Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WIPPS support system for adherence to rivaroxaban in atrial fibrillation
NL-OMON38596Withdrawn
- Sponsor
- Begeleide Zelfzorg
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Begeleide Zelfzorg. Primary endpoint: Percentage of compliant patients. Planned start Nov 2013; status: withdrawn.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON38596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38596.